Superluminal Medicines Inc.
Ryan Bloom currently serves as Vice President and Head of Business Development at Superluminal Medicines Inc. since November 2024. Prior to this role, Ryan held various positions at BlueRock Therapeutics, culminating in Senior Director of Business Development, where responsibilities included business development and new product planning. At Unum Therapeutics, Ryan contributed to corporate development, focusing on business strategy and financing. Earlier experience includes serving as Program Leader for Immuno-Oncology at Cofactor Genomics, where Ryan directed product development and partnerships, and founding Narus Biotechnologies, overseeing corporate development and fundraising. Ryan's academic background includes a PhD in Bioengineering from Stanford University and a B.S. in Chemical and Biomolecular Engineering from The Johns Hopkins University.
This person is not in any teams
Superluminal Medicines Inc.
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVIDIA and Gaingels.